Ola E. Dahl

Prevention of VTE in Orthopedic Surgery Patients

Yngve Falck–Ytter, Charles W. Francis, Norman A. Johanson et al. · CHEST Journal · 2012 · 1.9K citations · Full text

Medicine, Orthopedic Surgery, Surgery +17

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial

Bengt I. Eriksson, Ola E. Dahl, Nadia Rosencher et al. · The Lancet · 2007 · 1.1K citations

Medicine, Orthopedic Surgery, Pharmacotherapy +15

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

Ajay K. Kakkar, Benjamin Brenner, Ola E. Dahl et al. · The Lancet · 2008 · 1.1K citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +17

A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement

Bengt I. Eriksson, Lars C. Borris, Ola E. Dahl et al. · Circulation · 2006 · 332 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement

Joachim Stangier, Bengt I. Eriksson, Ola E. Dahl et al. · The Journal of Clinical Pharmacology · 2005 · 291 citations

Pharmacy, Pharmacokinetics, Pharmacology +13